目的：探讨DCCIK细胞治疗肾透明细胞癌临床疗效及治疗次数对患者预后的影响。方法：回顾性分析2004年1月至2011年6月在福建省肿瘤医院诊疗的100例肾透明细胞癌患者，其中63例在福建省肿瘤生物治疗重点实验室进行自体DCCIK细胞免疫治疗联合常规治疗为DCCIK细胞治疗组，其余37例未经DCCIK细胞治疗为对照组，比较两组患者的5年DFS和OS。治疗组按照DCCIK细胞治疗疗程数分成≤3个疗程组及>3个疗程组，分析DCCIK细胞治疗疗程数对肾透明细胞癌患者5年DFS和OS的相关性。结果：DCCIK细胞治疗组患者5年OS较对照组明显提高(81.05% vs 60.29%，P<0.05），但5年DFS无显著性差异（P>0.05）;DCCIK细胞治疗疗程数>3个的患者5年OS较对照组明显提高（P<0.05)，但5年DFS无显著性差异（P>0.05）。结论：自体DCCIK 细胞回输联合常规治疗手段治疗肾透明细胞癌更有生存优势，且DCCIK细胞治疗疗程数与肾透明细胞癌患者的预后密切相关。

Objective:To evaluate the clinical efficacy of adjuvant dendrtic cell (DC)cytokineinduced killer (CIK) cells immunotherapy and the effect of DCCIK cells treatment courses on the prognosis of patients with renal clear cell carcinoma. Methods: One hundred patients with renal clear cell carcinoma treated in Fujian Provincial Tumor Hospital from Jan, 2004 to Jun, 2011 were included in this retrospective study; 63 patients received DCCIK cells immunotherapy combined with conventional therapy were regarded as DCCIK cells treatment group, while the other 37 patients didn't receive DCCIK cells therapy were regarded as control group. The 5year DFS and OS of the two groups were compared. The treatment group was further subgrouped according to the course > 3 and course ≤3, and the 5year DFS and OS were further compared between the two subgroups. Results: Survival analysis showed the 5years overall survival (OS) rate was significantly higher in the DCCIK group compared with the control group (81.05% vs 60.29%, P<0.05), however, there was no significant difference in 5year DFS rate between two groups. Further subgroup analysis stratified according to the course of DCCIK cells treatment showed that the 5years OS was significantly improved in the group with course greater than 3 (P<0.05), although there was no significant difference in 5years DFS rate between two subgroups (P>0.05). Conclusion: Our results demonstrated that renal carcinoma patients could benefit from autologous DCCIK cells immunotherapy in combination with conventional therapies in terms of increasing overall survival. And the course of DCCIK cells treatment is closely related with the prognosis of patients with renal cell carcinoma.

福建省自然基金资助项目（No.2016J01514）；福建省科技计划项目（No.2017Y0022）